Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
April 16, 2008

Anjin Group Receives $2.9M from Leukemia & Lymphoma Society

  • The Leukemia & Lymphoma Society (LLS) and Anjin Group kicked off a three-year collaborative research program with $2.9 million. This marks the first drug development alliance to be funded through LLS' Therapy Acceleration Program (TAP).

    The Anjin Group will use the money to accelerate development of a fusion toxin protein for the treatment of acute myelogenous leukemia (AML). Continued funding will depend on meeting certain milestones.

    Anjin’s therapeutic platform for blood cancers, brain cancer, and other diseases is based on the fusion of a modified form of diphtheria toxin to proteins capable of selectively targeting cancerous and diseased cells. The company reports that its technology can be deployed with a variety of cell-surface receptors that are preferentially expressed on certain cell types to develop therapies with greater specificity and fewer side effects than existing drugs.

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.